Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 10/20 | 0.70 |
| ▸ | PGR | P06401 | 6/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.70 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.70 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.70 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.70 |
| ▸ | IL5 | P05113 | 1/20 | 0.70 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.70 |
| ▸ | AR | P10275 | 1/20 | 0.70 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.70 |
| ▸ | MMP9 | P14780 | 1/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.70 |
| ▸ | THPO | P40225 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | BLM | P54132 | 1/20 | 0.70 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13393081 | 1.00 | NR3C1 (0.70) | NR3C1PGRCYP3A4HIF1ALMNA | |
| SCHEMBL13393089 | 1.00 | NR3C1 (0.70) | NR3C1PGRCYP3A4HIF1ALMNA | |
| SCHEMBL13393103 | 1.00 | NR3C1 (0.70) | NR3C1PGRCYP3A4HIF1ALMNA | |
| SCHEMBL13393086 | 1.00 | NR3C1 (0.70) | NR3C1PGRCYP3A4HIF1ALMNA | |
| SCHEMBL3305296 | 0.99 | NR3C1 (0.69) | NR3C1PGRCYP3A4HIF1ALMNA | |
| SCHEMBL3305265 | 0.96 | NR3C1 (0.76) | NR3C1PGRCYP3A4HIF1ALMNA | |
| SCHEMBL19583457 | 0.96 | NR3C1 (0.76) | NR3C1PGRCYP3A4HIF1ALMNA | |
| SCHEMBL19583464 | 0.96 | NR3C1 (0.76) | NR3C1PGRCYP3A4HIF1ALMNA | |
| SCHEMBL18051174 | 0.96 | NR3C1 (0.76) | NR3C1PGRCYP3A4HIF1ALMNA | |
| Budesonide SCHEMBL3304441 | 0.89 | NR3C1 (0.80) | NR3C1PGRCYP3A4HIF1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220370370-A1 | LIPID NANOPARTICLES COMPRISING LIPOPHILIC ANTI-INFLAMMATORY AGENTS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2022-11-24 | — | — | US | claimed |
| US-11458106-B2 | Lipid nanoparticles comprising lipophilic anti-inflammatory agents and methods of use thereof | ASTRAZENECA AB (SE) | 2022-10-04 | — | — | US | claimed |
| CN-109152735-B | Lipid nanoparticles comprising lipophilic anti-inflammatory agents and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2022-03-11 | — | — | CN | claimed |
| EP-3454835-B1 | LIPID NANOPARTICLES COMPRISING LIPOPHILIC ANTI-INFLAMMATORY AGENTS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2021-03-31 | — | — | EP | claimed |
| EP-3454835-A1 | LIPID NANOPARTICLES COMPRISING LIPOPHILIC ANTI-INFLAMMATORY AGENTS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2019-03-20 | — | — | EP | claimed |
| CN-109152735-A | Lipidic nanoparticles and its application method comprising lipophilicity anti-inflammatory agent | 阿斯利康(瑞典)有限公司 | 2019-01-04 | — | — | CN | claimed |
| US-20170367988-A1 | LIPID NANOPARTICLES COMPRISING LIPOPHILIC ANTI-INFLAMMATORY AGENTS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2017-12-28 | — | — | US | claimed |
| WO-2017194454-A1 | LIPID NANOPARTICLES COMPRISING LIPOPHILIC ANTI-INFLAMMATORY AGENTS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2017-11-16 | — | — | WO | claimed |
| EP-2121723-A2 | FATTY ACID ESTERS OF GLUCOCORTICOIDS AS ANTI-INFLAMMATORY AND ANTI-CANCER AGENTS | Clavis Pharma ASA (NO) | 2009-11-25 | — | — | EP | claimed |
| WO-2008115069-A2 | FATTY ACID ESTERS OF GLUCOCORTICOIDS AS ANTI-INFLAMMATORY AND ANTI-CANCER AGENTS | CLAVIS PHARMA ASA (NO) | 2008-09-25 | — | — | WO | claimed |
| US-20220370370-A1 | LIPID NANOPARTICLES COMPRISING LIPOPHILIC ANTI-INFLAMMATORY AGENTS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2022-11-24 | — | — | US | disclosed |
| US-11458106-B2 | Lipid nanoparticles comprising lipophilic anti-inflammatory agents and methods of use thereof | ASTRAZENECA AB (SE) | 2022-10-04 | — | — | US | disclosed |
| CN-109152735-B | Lipid nanoparticles comprising lipophilic anti-inflammatory agents and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-3454835-B1 | LIPID NANOPARTICLES COMPRISING LIPOPHILIC ANTI-INFLAMMATORY AGENTS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2021-03-31 | — | — | EP | disclosed |
| EP-3454835-A1 | LIPID NANOPARTICLES COMPRISING LIPOPHILIC ANTI-INFLAMMATORY AGENTS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2019-03-20 | — | — | EP | disclosed |
| WO-2017194454-A1 | LIPID NANOPARTICLES COMPRISING LIPOPHILIC ANTI-INFLAMMATORY AGENTS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2017-11-16 | — | — | WO | disclosed |
| US-9428540-B2 | Fatty acid esters of glucocorticoids as anti-inflammatory and anti-cancer agents | CLAVIS PHARMA ASA (NO) | 2016-08-30 | — | — | US | disclosed |
| US-20100099654-A1 | FATTY ACID ESTERS OF GLUCOCORTICOIDS AS ANTI-INFLAMMATORY AND ANTI-CANCER AGENTS | CLAVIS PHARMA ASA (NO) | 2010-04-22 | — | — | US | disclosed |
| EP-2121723-A2 | FATTY ACID ESTERS OF GLUCOCORTICOIDS AS ANTI-INFLAMMATORY AND ANTI-CANCER AGENTS | Clavis Pharma ASA (NO) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008115069-A2 | FATTY ACID ESTERS OF GLUCOCORTICOIDS AS ANTI-INFLAMMATORY AND ANTI-CANCER AGENTS | CLAVIS PHARMA ASA (NO) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099654-A1 | FATTY ACID ESTERS OF GLUCOCORTICOIDS AS ANTI-INFLAMMATORY AND ANTI-CANCER AGENTS | ELOVL1, ELOVL5, NR3C1 | NR3C1 3/4885PGR 312/4885CYP3A4 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.